Soleno Therapeutics Inc (SLNO) — Capital Reinvestment Ratio

Latest as of March 2026: 0.00x

Soleno Therapeutics Inc (SLNO) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($25.98 Million) in capital expenditures ($40.00K). Check Soleno Therapeutics Inc tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

$25.98 Million

USD

Capital Expenditures

$40.00K

USD

Data as of

Mar 2026

Most recent filing

Soleno Therapeutics Inc Capital Reinvestment Ratio (2025–2025)

This chart tracks Soleno Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see SLNO cash generation efficiency.

Annual Capital Reinvestment Ratio for Soleno Therapeutics Inc (2025–2025)

Year-by-year Capital Reinvestment Ratio for Soleno Therapeutics Inc from 2025 to 2025. See Soleno Therapeutics Inc (SLNO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2025	0.00x	$46.80 Million	$73.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow